trial

Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

NCTId NCT06060886
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 244 (estimated)
Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER)
Primary completion 2025-06-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
244 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-11-01
Primary completion
2025-06-01
Eligibility
ALL · 15 Years · 40 Years

Interventions & indications

Drugs
AripiprazolePaliperidone

Sponsors

Consorcio Centro de Investigación Biomédica en Red (CIBER)Lead Sponsor
Instituto de Salud Carlos IIICollaborator

Investigators

1
Javier Labad Arias, MD, PhDPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
244
Phase
PHASE4
Primary Completion Date
2025-06-01
Status
UNKNOWN
relationships
The graph out of here
drug
Aripiprazole
drug
Paliperidone
drug
lead_sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
company
collaborator
Instituto de Salud Carlos III
company
indication
Diabetes
indication
Lipid Metabolism Disorders
indication
Treatment-resistant Schizophrenia
indication
investigator
Javier Labad Arias, MD, PhD
person